A novel diagnostic radiotracer can help estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adults being evaluated for Alzheimer’s disease (AD).
Developed by Avid Radiopharmaceuticals (Philadelphia, PA, USA), a wholly owned subsidiary of Eli Lilly (Indianapolis, IN, USA), Tauvid (flortaucipir18F) radiotracer is a small-molecule selective positron emission tomography (PET) imaging agent that binds to aggregated tau protein, which in the brains of patients with AD combine to form NFTs, one of the two components required for the neuro-pathological diagnosis of AD. The safety and effectiveness of the tau tracer was demonstrated in two clinical studies.
To read more please visit:
Source: MedImaging